Batten disease

Batten disease
Classification and external resources
Specialty endocrinology
ICD-10 E75.4
ICD-9-CM 330.1
OMIM 204200
DiseasesDB 31534
MeSH D009472

Batten disease (also known as Spielmeyer-Vogt-Sjögren-Batten disease) is an extremely rare and fatal autosomal recessive neurodegenerative disorder that begins in childhood. It is the most common form of a group of disorders called the neuronal ceroid lipofuscinoses (NCLs).

Although Batten disease is usually regarded as the juvenile form of NCL (or "type 3"), some physicians use the term Batten disease to describe all forms of NCL. Historically, the NCLs were classified by age of disease onset as infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL).[1]

At least twenty genes have been identified in association with Batten disease, but juvenile NCL, the most prevalent form of Batten disease, has been linked to mutations in the CLN3 gene.[2][3]

Signs and symptoms

Early signs and symptoms of the disorder usually appear around ages 2–10, with gradual onset of vision problems, or seizures. Early signs may be subtle personality and behavior changes, slow learning or regression, repetitive speech or echolalia, clumsiness, or stumbling. There may be slowing head growth in the infantile form, poor circulation in lower extremities (legs and feet), decreased body fat and muscle mass, curvature of the spine, hyperventilation and/or breath-holding spells, teeth grinding, and constipation.

Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight, speech and motor skills. Eventually, children with Batten disease become blind, bedridden, demented, and die. Batten disease is a terminal disease; life expectancy varies depending on the type or variation.

Females with juvenile Batten disease show first symptoms a year later than males but on average die a year sooner.[4]

Cause

Batten disease is caused by genetic mutations that cause lipofuscins to accumulate within the body's tissues. These substances consist of fats and proteins and form certain distinctive deposits that cause the symptoms and can be seen under an electron microscope. The diagnosis of Batten disease is based on the presence of these deposits in skin samples as well as other criteria. Eight genes have now been identified that cause different types of Batten disease in children or adults, more having yet to be identified. Two of these genes encode enzymes. The function of most of these genes is still unknown. The identification of these genes opens up the possibility of gene replacement therapy or other gene-related treatments. Batten disease is very rare and occurs in an estimated 2 to 4 out of every 100,000 births in the United States.[5]

Genetics

Batten disease has an autosomal recessive pattern of inheritance.

Batten disease is inherited primarily in an autosomal recessive pattern, but it varies by age. In cases involving children, it is only inherited as an autosomal recessive trait. In adults, the inheritance pattern is still autosomally recessive but there is also a chance of it being inherited in an autosomal dominant fashion as well. Eight genes have been identified in the variety of NCLs, mutations in which contribute to the development of the phenotypic trait of the disorders:

Diagnosis

In many instances, Batten disease is initially seen by an ophthalmologist during an eye exam because one of the first signs is vision loss. Even though it is also seen in a variety of other diseases as well, a loss of ocular cells should be a warning sign of Batten Disease potentially being present. If Batten Disease is a possible diagnosis for an individual, a variety of tests are run to confirm including:

Blood or urine tests. These tests can detect abnormalities that may indicate Batten disease. For example, elevated levels of a chemical called dolichol are found in the urine of many individuals with NCL. The presence of vacuolated lymphocytes—white blood cells that contain holes or cavities (observed by microscopic analysis of blood smears)—when combined with other findings that indicate NCL, is suggestive for the juvenile form caused by CLN3 mutations.

Skin or tissue sampling. The doctor can examine a small piece of tissue under an electron microscope. The powerful magnification of the microscope helps the doctor spot typical NCL deposits. These deposits are common in skin cells, especially those from sweat glands.

Electroencephalogram (EEG). An EEG uses special patches placed on the scalp to record electrical currents inside the brain. This helps doctors see telltale patterns in the brain's electrical activity that suggest an individual has seizures.

Electrical studies of the eyes. These tests, which include visual-evoked responses and electroretinograms, can detect various eye problems common in childhood NCLs.

Computed tomography (CT) or magnetic resonance imaging (MRI). Diagnostic imaging can help doctors look for changes in the brain's appearance. CT uses x-rays and a computer to create a sophisticated picture of the brain's tissues and structures, and may reveal brain areas that are decaying, or “atrophic,” in persons with NCL. MRI uses a combination of magnetic fields and radio waves, instead of radiation, to create a picture of the brain.

Measurement of enzyme activity. Measurement of the activity of palmitoyl-protein thioesterase involved in CLN1, the acid protease involved in CLN2, and, though more rare, cathepsin D activity involved in CLN10, in white blood cells or cultured skin fibroblasts (cells that strengthen skin and give it elasticity) can be used to confirm or rule out these diagnoses.

DNA analysis. If families where the mutation in the gene for CLN3 is known, DNA analysis can be used to confirm the diagnosis or for the prenatal diagnosis of this form of Batten disease. When the mutation is known, DNA analysis can also be used to detect unaffected carriers of this condition for genetic counseling. If a family mutation has not previously been identified or if the common mutations are not present, recent molecular advanced have made it possible to sequence all of the known NCL genes, increasing the chances of finding the responsible mutation(s).[6]

Treatment

Batten disease is a terminal illness, with no cure. Palliative treatment is symptomatic and supportive.

Research

In June 1987, a Phase I clinical trial was launched at Weill Medical College of Cornell University to study a gene therapy method for treatment of the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL). The experimental drug works by delivering a gene transfer vector called AAV2CUhCLN2 to the brain.[7] Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children.[8]

In November 2006, after receiving FDA clearance, neurosurgeon Nathan Selden, pediatrician Bob Steiner, and colleagues at Doernbecher Children's Hospital at Oregon Health & Science University began a clinical study in which purified neural stem cells were injected into the brain of Daniel Kerner, a six-year-old child with Batten disease, who had lost the ability to walk and talk. This patient was the first of six to receive the injection of a stem cell product from StemCells Inc., a Palo Alto biotech company. These are believed to be the first-ever transplants of fetal stem cells into the human brain.[9] By early December, the child had recovered well enough to return home, and it was reported that there were some signs of speech returning.[10] Daniel Kerner died on April 12, 2010.[11] The main goal of Phase I clinical trials, however, was to investigate the safety of transplantation. Overall, the Phase I data demonstrated that high doses of human neural stem cells, delivered by a direct transplantation procedure into multiple sites within the brain, followed by twelve months of immunosuppression, were well tolerated by all six patients enrolled in the trial. The patients’ medical, neurological and neuropsychological conditions, following transplantation, appeared consistent with the normal course of the disease.[12]

Mycophenolate mofetil is being tested to determine its ability to safely slow or halt neurodegeneration.[13][14] A non-randomised safety and efficacy trial of a gene transfer vector is underway.[15]

History

Batten disease is named after the British pediatrician Frederick Batten, who first described it in 1903.[16][17] Also known as Spielmeyer-Vogt-Sjögren-Batten disease, it is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs). Although Batten disease is usually regarded as the juvenile form of NCL, some physicians use the term Batten disease to describe all forms of NCL.

See also

Wikimedia Commons has media related to Batten disease.

References

  1. ↑ Hobert JA, Dawson G (October 2006). "Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future". Biochimica et Biophysica Acta 1762 (10): 945–53. doi:10.1016/j.bbadis.2006.08.004. PMID 17049436.
  2. ↑ Rakheja D, Narayan SB, Bennett MJ (September 2007). "Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update". Current Molecular Medicine 7 (6): 603–8. doi:10.2174/156652407781695729. PMID 17896996.
  3. ↑ Cooper JD (June 2008). "Moving towards therapies for juvenile Batten disease?". Experimental Neurology 211 (2): 329–31. doi:10.1016/j.expneurol.2008.02.016. PMID 18400221.
  4. ↑ Cialone J, Adams H, Augustine EF; et al. (May 2012). "Females experience a more severe disease course in Batten disease". Journal of Inherited Metabolic Disease 35 (3): 549–55. doi:10.1007/s10545-011-9421-6. PMC 3320704. PMID 22167274.
  5. ↑ http://www.bdsra.org/what-is-batten-disease/about-batten-disease/[]
  6. ↑ NIH
  7. ↑ Clinical trial number NCT00151216 for "Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis" at ClinicalTrials.gov
  8. ↑ Worgall S, Sondhi D, Hackett NR; et al. (May 2008). "Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA". Human Gene Therapy 19 (5): 463–74. doi:10.1089/hum.2008.022. PMID 18473686.
  9. ↑ "A stem cell first at OHSU" The Portland Tribune, Nov 24, 2006
  10. ↑ http://www.technologyreview.com/read_article.aspx?id=17888&ch=biotech[]
  11. ↑ http://writethehappyending.com/tag/daniel-kerner/
  12. ↑ "StemCells: Enter Date".
  13. ↑ http://www.medicalnewstoday.com/releases/227090.php[]
  14. ↑ Clinical trial number NCT01399047 for "Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JUMP)" at ClinicalTrials.gov
  15. ↑ Clinical trial number NCT01161576 for "Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis" at ClinicalTrials.gov
  16. ↑ synd/7 at Who Named It?
  17. ↑ Batten FE (1902). "Cerebral degeneration with symmetrical changes in the maculae in two members of a family". Transactions of the Ophthalmological Societies of the United Kingdom 23: 386–90.

External links

This article is issued from Wikipedia - version of the Wednesday, March 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.